Navellier & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Navellier & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,477	Closed	-$406K	–	322
2016 Q2	$406K	Buy	3,477 +17	+0.5%	+$2.41K	0.06%	154
2016 Q1	$482K	Sell	3,460 -70	-2%	-$10.3K	0.06%	127
2015 Q4	$673K	Sell	3,530 -136	-4%	-$23.8K	0.07%	104
2015 Q3	$573K	Hold	3,666	–	–	0.06%	136
2015 Q2	$663K	Hold	3,666	–	–	0.06%	161
2015 Q1	$635K	Hold	3,666	–	–	0.06%	159
2014 Q4	$678K	Sell	3,666 -77	-2%	-$14.3K	0.03%	150
2014 Q3	$621K	Hold	3,743	–	–	0.03%	151
2014 Q2	$585K	Sell	3,743 -517	-12%	-$81.6K	0.03%	164
2014 Q1	$648K	Sell	4,260 -257	-6%	-$40.9K	0.03%	134
2013 Q4	$600K	Sell	4,517 -4,885	-52%	-$586K	0.03%	151
2013 Q3	$1.09M	Sell	9,402 -4,098	-30%	-$450K	0.03%	119
2013 Q2	$1.25M	Buy	+13,500	New	+$1.3M	0.06%	92

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Navellier & Associates's ALXN Position: Q3 2016 in Review

Navellier & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 3,477 shares — an estimated $406K sold.

Navellier & Associates first reported a position in ALXN in Q2 2013 and held it in 13 quarters. The position peaked at $1.25M in Q2 2013. 519 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

Navellier & Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Navellier & Associates sold 3,477 Alexion Pharmaceuticals shares in Q3 2016, an estimated $406K.
Navellier & Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Navellier & Associates's Alexion Pharmaceuticals position peaked at $1.25M in Q2 2013.
519 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Navellier & Associates's 13F filing for Q3 2016, filed 24 Oct 2016.